Print

Martek Biosciences (MATK) To Supply Proprietary Protein Detection Dye To Beckman Coulter, Inc. (BEC) 
10/19/2005 5:12:04 PM

COLUMBIA, Md., Nov. 4 /PRNewswire-FirstCall/ -- Martek Biosciences Corporation announced today that it has entered into a 10-year supply agreement with Beckman Coulter effective immediately. Under terms of the agreement, Beckman Coulter has non-exclusive rights, except for IVD uses, to Martek's proprietary PBXL-1 protein detection dye. Beckman Coulter is expecting to utilize the dye on a variety of its research platforms, beginning initially with protein assay research applications on its A2(TM) MicroArray System.

"The agreement with Beckman Coulter sets the stage for expanded research applications in proteomics and genomics using Martek's proprietary PBXL-1 technology," said Henry Linsert, Jr., Chairman and CEO of Martek Biosciences Corporation. "Introduced on Beckman Coulter's A2 MicroArray System, our dye can provide superior protein detection for highly efficient protein assay research."

The PBXL-1 protein detection system combines the sensitivity of enzymatic amplification with the instant results of direct fluorescent dyes. PBXL-1 is part of Martek's series of fluorescent dyes which are up to 15 times more intense than the next brightest dyes, enabling researchers to miniaturize immunoassays which results in lower costs and decreased analysis time.

Martek Biosciences Corporation develops, manufactures and sells products from microalgae. The Company's products include: (1) specialty, nutritional oils for infant formula that aid in the development of the eyes and central nervous system in newborns; (2) nutritional supplements and food ingredients that may play a beneficial role in promoting mental and cardiovascular health throughout life; and (3) new, powerful fluorescent markers for diagnostics, rapid miniaturized screening, and gene and protein detection.

This press release contains forward-looking statements regarding the commercialization of Martek's products. Such statements involve risks and uncertainties that could cause future actual results to differ due to a variety of risk factors, including without limitation those factors set forth in Martek's filings with the Securities and Exchange Commission.

CONTACT: Pete Buzy, Chief Financial Officer of Martek Biosciences Corporation, +1-410-740-0081

Martek Biosciences Corporation

CONTACT: Pete Buzy, Chief Financial Officer of Martek BiosciencesCorporation, +1-410-740-0081


//-->